The primary goal of the CETR Administrative Core (Core A) is to promote success for all CETR programs including research programs and cores, supplemental research projects, financial monitoring and oversight, compliance and regulatory activities, biosafety and security issues, for all personnel, materials, data and facilities associated with CCTRHIB programs. The Core will work closely with the Scientific Advisory Board to assure that excellent progress is made on all projects, and that innovative supplemental projects are being funded. The Administrative Core is ultimately responsible for ensuring that the mission of this CETR for novel vaccine technology platform for high medical need infectious is met. Under Dr. Jenny Ting, Program Director and Dr. Barbara Vilen, Associate Director, the Administrative Core supports the scientific and translational goals as follows: (1) Execute day-to-day operations and management, including monitoring of expenditures, addressing grant management issues as well as unexpected issues that arise. (2) Managing, coordinating, and supervising Scientific Projects 1-3 and Cores B-D. (3) Coordinate the review activities ofthe advisory committee, both reviews of Projects and Cores and reviews of supplemental applications. (4) Oversee activities of the research programs, core activities, supplemental research projects to assure proper compliance and regulatory activities, biosafety and security issues for all personnel, materials, data publication and resource sharing, and technology transfer/intellectual properties necessary for product development associated with Center programs.
The Administrative Core is ultimately responsible for ensuring the successful completion of the Center's mission to advance medical countermeasures to Emerging and Re-emerging Infectious Diseases. The Scientific Administrators, the Administrative Staff and Regulatory personnel will work together toward that goal. The Administrative Core is ultimately responsible for ensuring the successful completion of the Center's mission to advance medical countermeasures to Emerging and Re-emerging Infectious Diseases. The Scientific Administrators, the Administrative Staff and Regulatory personnel will work together toward that goal.
|Kai, Marc P; Brighton, Hailey E; Fromen, Catherine A et al. (2016) Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. ACS Nano 10:861-70|
|Fromen, Catherine A; Rahhal, Tojan B; Robbins, Gregory R et al. (2016) Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells. Nanomedicine 12:677-87|
|Fromen, Catherine A; Robbins, Gregory R; Shen, Tammy W et al. (2015) Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization. Proc Natl Acad Sci U S A 112:488-93|
|Cheong, Woo-Chang; Kang, Hye-Ri; Yoon, Hyunyee et al. (2015) Influenza A Virus NS1 Protein Inhibits the NLRP3 Inflammasome. PLoS One 10:e0126456|
|Roberts, Reid A; Eitas, Timothy K; Byrne, James D et al. (2015) Towards programming immune tolerance through geometric manipulation of phosphatidylserine. Biomaterials 72:1-10|
|Callaway, Justin B; Smith, Scott A; Widman, Douglas G et al. (2015) Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1Î² Secretion: A Primary Human Monocyte Model. PLoS One 10:e0136708|
|Callaway, Justin B; Smith, Scott A; McKinnon, Karen P et al. (2015) Spleen Tyrosine Kinase (Syk) Mediates IL-1Î² Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection. J Biol Chem 290:17306-20|
|Robbins, Gregory R; Roberts, Reid A; Guo, Haitao et al. (2015) Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model. Nanomedicine 11:589-99|
|Mueller, Sarah N; Tian, Shaomin; DeSimone, Joseph M (2015) Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity. Mol Pharm 12:1356-65|